A case of recurrent pancreatic cancer responding to TS-1 combined gemcitabine chemotherapy after UFT combined gemcitabine chemotherapy resulting progressive disease
Sunagozaka, H.; Yamashita, T.; Kagaya, T.; Kato, Y.; Kaneko, S.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(6): 829-832
2006
ISSN/ISBN: 0385-0684 PMID: 16770107 Document Number: 595925
The patient diagnosed as recurrent pancreatic cancer was treated with UFT combined gemcitabine (GEM) chemotherapy. After one cycle of therapy, the anti-tumor effect was progressive disease with obstructive jaundice and enlargement of lymph node metastasis and liver metastasis. The chemotherapy was changed to TS-1 combined GEM chemotherapy and resulted in partial response. Only grade 3 leukopenia was observed as an adverse effect. Some cases may be effectively treated by TS-1 combined chemotherapy after treatment failure of UFT combined GEM chemotherapy. This therapy is simple and possible to continue safely on an ambulatory basis while maintaining quality of life.